Jan 10, 2022 / 02:00PM GMT
Eric William Joseph - JPMorgan Chase & Co, Research Division - VP & Senior Analyst
All right. Good morning, and welcome to the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst with the firm. Thanks for joining us. Our next presenting company this morning is Novavax and here to talk to us about the company is CEO, Stan Erck. Quick programming note, there is a Q&A session after the presentation. Feel free to submit a question by clicking the "Ask a Question" icon. With that, Stan, thanks for joining us.
Stanley Charles Erck - Novavax, Inc. - President, CEO & Director
Eric, thank you very much, and thank you, everyone, for joining us this morning. I'm pleased to be here today to discuss the incredible progress Novavax has made over recent months as well as our many substantial milestones ahead in 2022. So let's turn to Slide 2. Before I begin today's presentation, I need to remind you that we will be making forward-looking statements during the conference, which are based on our current expectations. We encourage
Novavax Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers